Mersana Therapeutics Inc. announced Feb. 3 that Takeda Pharmaceutical Co. Ltd. will pay $40m upfront for rights to XMT-1522, an antibody-drug conjugate (ADC) that targets HER2. Mersana will receive another $20m once an IND is accepted by the US FDA, which is expected in mid-2016.
Mersana will be responsible for preclinical and Phase I work, while the pair intend to work together on development beyond that point. Mersana retains US and Canadian rights to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?